ATA901993A - Salze von peptiden mit carboxy-terminierten polyestern - Google Patents

Salze von peptiden mit carboxy-terminierten polyestern

Info

Publication number
ATA901993A
ATA901993A AT0901993A AT901993A ATA901993A AT A901993 A ATA901993 A AT A901993A AT 0901993 A AT0901993 A AT 0901993A AT 901993 A AT901993 A AT 901993A AT A901993 A ATA901993 A AT A901993A
Authority
AT
Austria
Prior art keywords
carboxy
terminated polyesters
peptide salts
peptide
salts
Prior art date
Application number
AT0901993A
Other languages
English (en)
Other versions
AT407702B (de
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of ATA901993A publication Critical patent/ATA901993A/de
Application granted granted Critical
Publication of AT407702B publication Critical patent/AT407702B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
AT0901993A 1992-05-28 1993-05-25 Salze von peptiden mit carboxy-terminierten polyestern AT407702B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB@@@@A GB9211268D0 (en) 1992-05-28 1992-05-28 Salts of basic peptides with carboxyterminated polyesters
PCT/GB1993/001079 WO1993024150A1 (en) 1992-05-28 1993-05-25 Salts of peptides with carboxy-terminated polyesters

Publications (2)

Publication Number Publication Date
ATA901993A true ATA901993A (de) 2000-10-15
AT407702B AT407702B (de) 2001-05-25

Family

ID=10716132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0901993A AT407702B (de) 1992-05-28 1993-05-25 Salze von peptiden mit carboxy-terminierten polyestern

Country Status (33)

Country Link
US (3) US5889110A (de)
JP (1) JPH08501064A (de)
KR (1) KR100293882B1 (de)
AT (1) AT407702B (de)
AU (1) AU682310B2 (de)
BE (1) BE1006143A3 (de)
CA (1) CA2136751C (de)
CH (2) CH688911A5 (de)
CZ (1) CZ292449B6 (de)
DE (2) DE4392401B4 (de)
DK (1) DK176134B1 (de)
ES (1) ES2107357B1 (de)
FI (1) FI112603B (de)
FR (1) FR2691631B1 (de)
GB (3) GB9211268D0 (de)
GR (1) GR1001550B (de)
HK (1) HK133097A (de)
HU (1) HUT70177A (de)
IE (1) IE74715B1 (de)
IL (1) IL105710A (de)
IT (1) IT1271139B (de)
LU (1) LU88559A1 (de)
MC (1) MC2330A1 (de)
NL (1) NL195056C (de)
NO (1) NO311006B1 (de)
NZ (1) NZ252268A (de)
RU (1) RU2152225C1 (de)
SE (1) SE501970C2 (de)
SG (1) SG44645A1 (de)
SK (1) SK280320B6 (de)
TW (1) TW223018B (de)
WO (1) WO1993024150A1 (de)
ZA (1) ZA933358B (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP1240896A3 (de) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Einkapseln von wasserlöslischen Peptiden
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040142475A1 (en) * 2000-06-02 2004-07-22 Barman Shikha P. Delivery systems for bioactive agents
ATE350015T1 (de) * 2000-09-28 2007-01-15 Novartis Vaccines & Diagnostic Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6873915B2 (en) * 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
EP1429731B1 (de) * 2001-09-19 2007-01-03 Elan Pharma International Limited Nanopartikelzusammensetzungen enthaltend insulin
ES2561108T3 (es) * 2001-10-19 2016-02-24 Idexx Laboratories, Inc. Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
KR20040058101A (ko) * 2001-11-14 2004-07-03 알자 코포레이션 카테터 주입가능한 데포 조성물 및 그의 용도
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
EP1446100B1 (de) * 2001-11-14 2011-05-04 Durect Corporation Injizierbare depotzusammensetzungen und deren verwendung
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
ATE374598T1 (de) * 2002-03-15 2007-10-15 Alrise Biosystems Gmbh Mikropartikel und verfahren zur deren herstellung
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
ES2605402T3 (es) * 2002-06-25 2017-03-14 Takeda Pharmaceutical Company Limited Procedimiento para producir una composición de liberación sostenida
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP2006503004A (ja) * 2002-07-31 2006-01-26 アルザ・コーポレーション 射出可能なデポ組成物及びその使用
DE60325742D1 (de) * 2002-07-31 2009-02-26 Alza Corp Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
ATE418323T1 (de) * 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
EP1660013A4 (de) 2003-08-26 2011-07-20 Gel Del Technologies Inc Protein-biomaterialien und biokoazervate und herstellungs- und verwendungsverfahren dafür
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
EP1691746B1 (de) 2003-12-08 2015-05-27 Gel-Del Technologies, Inc. Mukoadhäsive arzneimittelabgabevorrichtungen und verfahren zu ihrer herstellung und verwendung
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8945598B2 (en) * 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
EP1837014A1 (de) * 2006-03-21 2007-09-26 Hexal Ag Subkutane Implantate welche ein abbau-resistentes Polylactid-Polymer und ein LH-RH Analogon enthalten
ITMI20061538A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
EP1917971A1 (de) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Zusammensetzungen mit verlängerter Wirkstofffreigabe, enthaltend Polymere mit sehr niedrigem Molekulargewicht
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (de) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
RU2327459C1 (ru) * 2007-06-26 2008-06-27 Евгений Сергеевич Северин Лекарственное средство противомикробного действия, способ получения лекарственного препарата направленного действия, содержащего наночастицы
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
US20090163603A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends
US11890371B2 (en) 2007-12-26 2024-02-06 Petvivo Holdings, Inc. Biocompatible protein-based particles and methods thereof
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20110160159A1 (en) 2009-09-15 2011-06-30 John Ryan Treatment of cancer
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
KR20120098906A (ko) * 2009-12-22 2012-09-05 다케다 야쿠힌 고교 가부시키가이샤 서방성 제제
DE102010003615A1 (de) 2010-04-01 2011-10-06 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Herstellung eines Drug-Delivery-Systems auf der Basis von Polyelektrolytkomplexen
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
EP2585092A1 (de) 2010-06-24 2013-05-01 Torrent Pharmaceuticals Limited Pharmazeutische zusammensetzung mit goserelin für ein in-situ-implantat
BR112012032544A2 (pt) * 2010-06-25 2016-10-11 Takeda Pharmaceutical formulação de liberação prolongada, uso de um composto, e, método para produzir a formulação de liberação prolongada.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2835018C (en) 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
KR101467275B1 (ko) * 2011-12-19 2014-12-02 주식회사 삼양바이오팜 분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
RU2715714C2 (ru) * 2013-03-04 2020-03-03 Безен Хелткэа Люксембург Сарл Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
HUE070412T2 (hu) 2016-04-12 2025-06-28 Tonix Pharma Ltd Magnézium tartalmú oxitocin készítmények és alkamazási eljárásaik
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN110954491B (zh) * 2019-12-09 2022-11-15 北京博恩特药业有限公司 用于测量醋酸戈舍瑞林缓释植入剂体外溶出度的方法
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
EP4192509A1 (de) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Behandlung von krebs mit einem cyclodextrinhaltigen polymer-topoisomerase-inhibitor-konjugat und einem parp-inhibitor
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
MX2024001681A (es) 2021-08-05 2024-03-04 Medincell S A Composicion farmaceutica.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5005602A (en) * 1985-12-24 1991-04-09 Dover Corporation Poppet valve assembly
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
WO1992000718A1 (en) * 1990-07-03 1992-01-23 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IL96129A0 (en) * 1990-07-20 1991-07-18 Spectronix Ltd Method and apparatus for detecting a fire,explosion,or projectile-penetration in a monitored space
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

Also Published As

Publication number Publication date
NO311006B1 (no) 2001-10-01
NL9320034A (nl) 1995-04-03
RU94046097A (ru) 1996-09-20
FI112603B (fi) 2003-12-31
SE9404115D0 (sv) 1994-11-28
ITMI931099A0 (it) 1993-05-27
AT407702B (de) 2001-05-25
GB9423366D0 (en) 1995-01-25
NO944535L (no) 1995-01-25
SG44645A1 (en) 1997-12-19
GB9309645D0 (en) 1993-06-23
DK176134B1 (da) 2006-09-18
IL105710A0 (en) 1993-09-22
HU9403371D0 (en) 1995-02-28
NZ252268A (en) 1996-12-20
ES2107357A1 (es) 1997-11-16
GB9211268D0 (en) 1992-07-15
SE501970C2 (sv) 1995-07-03
MC2330A1 (fr) 1994-05-31
SE9404115L (sv) 1994-11-28
GB2282066A (en) 1995-03-29
FR2691631B1 (fr) 1995-06-09
CZ293794A3 (en) 1995-03-15
CZ292449B6 (cs) 2003-09-17
IE74715B1 (en) 1997-07-30
SK280320B6 (sk) 1999-11-08
US5889110A (en) 1999-03-30
CH690491A5 (de) 2000-09-29
FI945553L (fi) 1995-01-25
CA2136751C (en) 2006-10-31
ITMI931099A1 (it) 1994-11-27
AU682310B2 (en) 1997-10-02
ZA933358B (en) 1994-09-15
HK133097A (en) 1997-10-24
US20020198315A1 (en) 2002-12-26
CH688911A5 (de) 1998-05-29
HUT70177A (en) 1995-09-28
AU4084793A (en) 1993-12-30
SK143494A3 (en) 1995-07-11
NL195056C (nl) 2003-07-01
IL105710A (en) 2001-03-19
IT1271139B (it) 1997-05-27
WO1993024150A1 (en) 1993-12-09
DK135394A (da) 1994-11-28
GB2282066B (en) 1996-11-06
KR100293882B1 (ko) 2001-09-17
NO944535D0 (no) 1994-11-25
TW223018B (en) 1994-05-01
FI945553A0 (fi) 1994-11-25
IE930358A1 (en) 1993-12-01
ES2107357B1 (es) 1998-10-16
US6034175A (en) 2000-03-07
GR1001550B (el) 1994-04-29
DE4392401B4 (de) 2007-05-16
LU88559A1 (fr) 1995-04-05
FR2691631A1 (fr) 1993-12-03
BE1006143A3 (fr) 1994-05-24
CA2136751A1 (en) 1993-12-09
DE4392401T1 (de) 1997-07-24
JPH08501064A (ja) 1996-02-06
RU2152225C1 (ru) 2000-07-10

Similar Documents

Publication Publication Date Title
ATA901993A (de) Salze von peptiden mit carboxy-terminierten polyestern
NO942066L (no) Peptidderivater
DE4393381T1 (de) Peptide
FI940642L (fi) Imidatsolyyli-alkeenihapot
FI921740L (fi) Hybrid polypeptid
FI940945A7 (fi) Uusia isosteerisiä peptidejä
FI942289L (fi) Uusia substituoituja salisyylihappoja
DE69333329D1 (de) Polyesterfolie
DK6893D0 (da) Peptid
DE69132708D1 (de) Therapeutische Vervendung von Peptiden mit Thrombospondin - ähnlicher Aktivität
SE8803847A0 (sv) Neuromodulerande peptid
DE69213939D1 (de) Fahrzeugantriebssystem mit kraftstoffzufuhr von aussen
FI924570A7 (fi) Bentsimidatsolifosfonoaminohappoja
DK197989A (da) Peptidanaloger
DE69319472D1 (de) Orientierte Polyesterfolie
DE69309901D1 (de) Aminosäurederivate mit anticholecystokininwirkung
KR900700503A (ko) 펩티드
DE68920562D1 (de) Isomerisierung von Carbonsäuren.
FI934222A7 (fi) Pyridatsinonietikkahappoja
DE3872885D1 (de) Reduktion von carboxylendgruppen in polyester mit lactimaethern.
DE69322550D1 (de) Polyesterfilm
DE59302218D1 (de) Krempel- und Kardenantrieb
DE69323688D1 (de) Epitop-Peptide von menschlichem Parvovirus
SE9202754D0 (sv) Fulfilment
DE68914057D1 (de) Peptide.

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
ELJ Ceased due to non-payment of the annual fee